A Phase 1 interventional study of Tegoprazan 12.5mg and Tegoprazan 25mg in Healthy, sponsored by HK inno.N Corporation. Enrolling by invitation at 1 site in Korea, Republic of. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.
Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to explore pharmacokinetics, pharmacodynamics, and safety of tegoprazan 12.5 mg in healthy subjects when orally administered as a single dose or as multiple doses twice daily.
The secondary objectives of this study are
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical history
Clinical laboratory tests and (ECG)
Allergies and drug abuse
Prohibited concomitant medications/diets
Blood donation and transfusion
Pregnancy, breastfeeding, and non-use of
Others
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tegoprazan 12.5mg
Drug: Tegoprazan 12.5mg
Tegoprazan 25mg
Drug: Tegoprazan 25mg
Famotidine 20mg
Drug: Famotidine 20mg
Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
Also known as: Tegoprazan Tab. 12.5mg
Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
Also known as: K-CAB Tab. 25mg
Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
Also known as: Gaster Tab. 20 mg Dong-A
Cmax of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 1)
Time frame: Pre-dose(0 hour) up to 24 hours on Day 1
AUC0-t of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 1)
Time frame: Pre-dose(0 hour) up to 24 hours on Day 1
AUC0-∞ of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 1)
Time frame: Pre-dose(0 hour) up to 24 hours on Day 1
Tmax of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 1)
Time frame: Pre-dose(0 hour) up to 24 hours on Day 1
t1/2β of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 1)
Time frame: Pre-dose(0 hour) up to 24 hours on Day 1
CL/F of tegoprazan
Pharmacokinetic evaluation (Day 1)
Time frame: Pre-dose(0 hour) up to 24 hours on Day 1
Vd/F of tegoprazan
Pharmacokinetic evaluation (Day 1)
Time frame: Pre-dose(0 hour) up to 24 hours on Day 1
Css,max of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning) (-12, 0 hour) up to 24 hours on Day 14
Css,min of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
Css,avg of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
AUCtau,ss of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
Tmax,ss of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
t1/2β,ss of tegoprazan and tegoprazan's metabolite M1
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
CLss/F of tegoprazan
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
Vdss/F of tegoprazan
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
Accumulation index of tegoprazan
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
Fluctuation of tegoprazan
Pharmacokinetic evaluation (Day 14)
Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14
24-hour, daytime and nighttime mean pH
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
24-hour, daytime and nighttime median pH
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
24-hour, daytime and nighttime TpH>3(%)
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
24-hour, daytime and nighttime TpH>4(%)
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
24-hour, daytime and nighttime Δ TpH>3(%)
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
24-hour, daytime and nighttime Δ TpH>4(%)
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
24-hour, daytime and nighttime Δ mean pH
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
24-hour, daytime and nighttime Δ median pH
Pharmacodynamic evaluation
Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14
Started Mar 2024 (actual). Primary completion is estimated for Jul 2024, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan